The Drug Launches That Will Shape 2027

2027 will be a unique year for new drug launches.

Why? Because nearly two-thirds of the cohort are first-in-class.

Noteworthy drugs expected to be seeking a 2027 approval include Lilly’s retatrutide, Roche’s giredestrant and Vertex’s povetacicept. They are among over 60 launch candidates in Evaluate’s Key Potential Drug Launches in 2027 report, spanning 15 therapy areas.

Share:

Register today








About this webinar

Evaluate’s analysts will walk through some of the report’s findings, using proprietary forecasts and probability of success data to show where the value in the 2027 cohort sits and where competition is already heating up. You will leave with a clearer view of which launches are reshaping your markets, where clinical innovation lies, and where commercial risk is overtaking clinical risk.

The session will answer:

  • Which launches have the scale to reshape markets?
  • Where are new mechanisms entering established markets, and which rivals got there first?
  • Which near-term decisions and filings determine whether launches happen in 2027?
  • Which lesser-known assets deserve a place on the radar?

Join our analysts for a guided tour of the pipeline most likely to move markets in 2027. The session is 45 minutes, free to attend, and includes access to the materials afterwards.

Can’t make the live date? Register anyway and you’ll receive a recording once the event has taken place.

Speakers

Piotr Lis

Analyst, Evaluate

Nkiru Ibeanu

Analyst, Evaluate

Frequently Asked Questions

The 2027 cohort spans 15 therapy areas and includes 43 candidates that introduce a new drug class and 27 that could change the standard of care. With 34 already filed or marketed, many of these launches are close enough to plan around.

Drugs were chosen on regulatory position as of July 2026 and screened on indication-level financials, with no current US sales in the target indication or setting. To qualify, a drug needed to bring a new drug class, change the standard of care, or offer market potential of $1 billion or more.

The session looks at the highest-value launches, clinically innovative drugs, new mechanisms entering established markets, the regulatory decisions to track, and a set of lesser-known assets worth watching.

Anyone who needs a clear, evidence-based view of the 2027 launch landscape to inform pipeline, partnership, competitive or investment decisions.

A structured view of the launches most likely to shape markets in 2027, the evidence behind them, and the regulatory and commercial milestones to follow.

Explore all webinars